Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Dementia01:30

Dementia

584
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
584
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

738
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
738
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nutritional Assessment in Older Adults : MNA® 25 years of a Screening Tool and a Reference Standard for Care and Research; What Next?

The journal of nutrition, health & aging·2021
Same author

The INSPIRE Research Initiative: A Program for GeroScience and Healthy Aging Research Going from Animal Models to Humans and the Healthcare System.

The Journal of frailty & aging·2021
Same author

Frequency of Conditions Associated with Declines in Intrinsic Capacity According to a Screening Tool in the Context of Integrated Care for Older People.

The Journal of frailty & aging·2021
Same author

Framework Implementation of the INSPIRE ICOPE-CARE Program in Collaboration with the World Health Organization (WHO) in the Occitania Region.

The Journal of frailty & aging·2021
Same author

The INSPIRE Bio-Resource Research Platform for Healthy Aging and Geroscience: Focus on the Human Translational Research Cohort (The INSPIRE-T Cohort).

The Journal of frailty & aging·2021
Same author

Towards a Large-Scale Assessment of the Relationship between Biological and Chronological Aging: The INSPIRE Mouse Cohort.

The Journal of frailty & aging·2021
Same journal

Distinct spatial patterns of perivascular spaces enlargement for multiple and Co-existing pathologies of cognitive impairment.

The journal of prevention of Alzheimer's disease·2026
Same journal

Drawing a line: Differentiating mild from moderate dementia using the functional activities questionnaire.

The journal of prevention of Alzheimer's disease·2026
Same journal

The generalizability gap: anticoagulant exclusions and the "Enhanced Safety" of donanemab in the EU-eligible population.

The journal of prevention of Alzheimer's disease·2026
Same journal

Asia's dementia burden: from epidemiological description to prevention-oriented neurology.

The journal of prevention of Alzheimer's disease·2026
Same journal

The time interval from amyloid to tau PET positivity varies by age, sex and APOE-ε4 status.

The journal of prevention of Alzheimer's disease·2026
Same journal

Beyond target engagement: RNA therapeutics and the neuroimmune challenge in tauopathies.

The journal of prevention of Alzheimer's disease·2026
See all related articles

Related Experiment Video

Updated: Feb 17, 2026

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.2K

EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials.

P Aisen1, J Touchon, R Amariglio

  • 1PPaul Aisen, Alzheimer's Therapeutic Research Institute (ATRI), Keck School of Medicine, University of Southern California, San Diego, CA, USA, paisen@usc.edu.

The Journal of Prevention of Alzheimer'S Disease
|November 30, 2017
PubMed
Summary
This summary is machine-generated.

Clinical Trials in Alzheimer's Disease (CTAD) Task Force identified key challenges for future Alzheimer's disease (AD) treatment trials. Innovations in recruitment, outcome measures, and biomarker use are crucial for advancing AD research.

Keywords:
Alzheimer’s diseaseclinical trialscognitive compositescognitive outcome measuresinformant-reported outcome measuresmild behavioral impairmentmolecular imagingpatient-reported outcome measuressecondary prevention trials

More Related Videos

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

28.2K
A Fine Motor Task to Study Joint Kinematics in a Preclinical Model of Neurodegenerative Disease
05:39

A Fine Motor Task to Study Joint Kinematics in a Preclinical Model of Neurodegenerative Disease

Published on: June 13, 2025

926

Related Experiment Videos

Last Updated: Feb 17, 2026

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.2K
Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

28.2K
A Fine Motor Task to Study Joint Kinematics in a Preclinical Model of Neurodegenerative Disease
05:39

A Fine Motor Task to Study Joint Kinematics in a Preclinical Model of Neurodegenerative Disease

Published on: June 13, 2025

926

Area of Science:

  • Neurology
  • Clinical Trials
  • Alzheimer's Disease Research

Background:

  • The EU/US/Clinical Trials in Alzheimer's Disease (CTAD) Task Force convened to address challenges in Alzheimer's disease (AD) clinical trials.
  • Focus on prevention trials and the pre-clinical stage of AD treatment development.

Framework:

  • Reviewed lessons learned from ongoing and planned AD prevention trials.
  • Identified critical areas for improvement across all trial aspects.

Implementation:

  • Called for innovation in patient recruitment and retention strategies.
  • Emphasized the need for robust infrastructure development for clinical trials.
  • Discussed the selection of optimal outcome measures for assessing disease progression.

Implications:

  • Cognitive changes are key markers, but optimal assessment tools for clinically meaningful endpoints are needed.
  • Patient- and informant-reported outcomes present unique challenges but may offer valuable insights.
  • Imaging and other biomarkers are essential for maximizing trial efficiency and data acquisition.